FATE THERAPEUTICS INC
FATE evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $299.6M
- Cash Runway:
- 19.1 mo
What it means
What to watch
Prepared research question
What matters most for FATE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FATE
FATE Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs), with a lead candidate FT819 in Phase 2 for lupus nephritis and other indications.
Key risk: Cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
FATE Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs), with a lead candidate FT819 in Phase 2 for lupus nephritis and other indications.
- Cash & equivalents of $32.4M as of 2026-06-30 [sec]
- Total revenue of $2.1M and net loss of -$30.2M for the period ending 2026-06-30 [sec]
- Lead product candidate FT819 (iPSC-derived anti-CD19 CAR T-cell) is in Phase 2 for lupus nephritis and Phase 1 for B-cell mediated autoimmune disease [pipeline][news·2026-09-02]
- FT825 (iPSC-derived HER2-targeted CAR T-cell) is in Phase 1 for advanced solid tumors [pipeline]
- FDA selected FT819 into the CMC Development and Readiness Pilot (CDRP) program to support accelerated clinical timelines [news·2026-05-13]
What works
- Proprietary iPSC platform enables a renewable, clonal master cell line for consistent off-the-shelf manufacturing [sec_mda·as of 2026-08-13]
- FT819 has advanced to a potentially registrational Phase 2 trial (RECLAIM-LN) in lupus nephritis, indicating clinical progress [news·2026-09-02]
- FDA selection into the CDRP program provides enhanced regulatory communication to support CMC readiness [news·2026-05-13]
What to weigh
- No meaningful revenue from product sales expected for several years; company relies on external funding [sec_mda·as of 2026-08-13]
- Net loss of -$30.2M and cash of $32.4M as of 2026-06-30 imply a limited cash runway without additional financing [sec]
- FT819 faces a competitive landscape with 76 competitors in its target indications, including multiple Phase 2/3 programs [pipeline]
From the filings
Quoted directly from source documents.
Company is clinical-stage and uses iPSC-derived cellular immunotherapies
“We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the shelf cellular immunotherapies to patients.”
SEC MD&A · August 13, 2026
FT819 is in Phase 2 for lupus nephritis
“Fate Therapeutics starts Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis”
News · September 2, 2026
FT819 selected into FDA CDRP program
“FDA selects FT819 into the CDRP (CMC Development and Readiness Pilot) program enabling early and enhanced communication with the FDA to ensure CMC readiness for accelerated clinical timelines”
News · May 13, 2026
Catalyst timeline
- 2026-10-25 · Phase2_Start: A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants With Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma — This catalyst appears unrelated to FATE's pipeline; it may be a misattributed event.
Risks & what to watch (3)›
Key risks
- Cash runway — Cash of $32.4M as of 2026-06-30 may be insufficient to fund operations until revenue generation [sec]
- No product revenue — Company expects no meaningful product revenue for several years, relying on external financing [sec_mda·as of 2026-08-13]
- Competitive pressure — FT819 faces 76 competitors in its target indications, including Phase 2/3 programs [pipeline]
What to watch
- Initiation and data from Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis [news·2026-09-02]
- Clinical data presentations for FT819 and preclinical data for FT839 at upcoming conferences [news·2026-09-09]
- Cash position and any new financing or partnership announcements given limited runway [sec]
- Regulatory milestones from FDA CDRP program for FT819 [news·2026-05-13]
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run FATE THERAPEUTICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FATE THERAPEUTICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
19.1 months
D/E 0.70 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
155
Total value held
$83.2M
| Holder | Shares | Value |
|---|---|---|
| redmile group, llc | 12,872,946 | $15.4M |
| blackrock, inc. | 10,068,614 | $12.1M |
| vanguard capital management llc | 4,192,063 | $5.0M |
| vanguard portfolio management llc | 4,134,585 | $5.0M |
| two sigma investments, lp | 3,466,786 | $4.2M |
| johnson & johnson | 3,379,064 | $4.1M |
| aqr capital management llc | 3,001,521 | $3.6M |
| renaissance technologies llc | 2,974,683 | $3.6M |
| geode capital management, llc | 2,590,429 | $3.1M |
| state street corp | 2,263,173 | $2.7M |
Showing top 10 of 155 institutional holders of FATE THERAPEUTICS INC. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 10.0%
- Days to cover
- 8.9
- Shares short
- 10,255,224
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FATE short interestGovernance
Frequently asked questions
What is the AI investment thesis for FATE THERAPEUTICS INC?
FATE Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs), with a lead candidate FT819 in Phase 2 for lupus nephritis and other indications.
Who is the CEO of FATE THERAPEUTICS INC?
Dr. Bahram Valamehr M.B.A., Ph.D. is the chief executive officer of FATE THERAPEUTICS INC (FATE).
Where is FATE THERAPEUTICS INC headquartered?
FATE THERAPEUTICS INC (FATE) is headquartered in San Diego, CA, United States.
What therapeutic areas does FATE THERAPEUTICS INC focus on?
FATE THERAPEUTICS INC develops therapies across Oncology, Gene Therapy, Neurology, Immunology, Dermatology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.